RAS/MAPK/ERK Signaling: Oncogenic Mutations, RAF Dimerization, and Targeted Inhibition in Research

# RAS/MAPK/ERK Signaling: GTPase Cycle, RAF-MEK-ERK Cascade, and BRAF Inhibitor Mechanisms in Research

For Research Use Only (RUO). Not for use in humans or animals.

---

The RAS/MAPK/ERK pathway is the most frequently mutated oncogenic signaling axis in human cancer, with activating mutations in RAS family genes (KRAS, NRAS, HRAS) present in approximately 20-25% of all cancers, and activating BRAF mutations in an additional 8-10%. The pathway transmits mitogenic signals from receptor tyrosine kinases through a three-tier kinase cascade -- RAF -> MEK1/2 -> ERK1/2 -- to regulate proliferation, survival, differentiation, and migration. The mechanistic complexity of the pathway, including the paradoxical activation of ERK by first-generation BRAF inhibitors in RAS-mutant cells, has made it both a paradigm for cancer drug discovery and a rich subject for basic signaling research. This article provides a mechanistically detailed account of the RAS GTPase cycle, RAF kinase activation, ERK1/2 substrates, scaffolding proteins, negative feedback mechanisms, and the research tools used to dissect this pathway.

---

RAS GTPase Biology: Structure and the GTPase Cycle

RAS Family Members and Isoform-Specific Biology

Three closely related RAS proto-oncogenes encode four protein isoforms (K-RAS4A, K-RAS4B, N-RAS, H-RAS), all ~21 kDa GTPases sharing 85-90% sequence identity in the G-domain but differing in their C-terminal hypervariable regions (HVR), which dictate membrane targeting:

• •KRAS4B: farnesylated (CAAX motif, C185) + polybasic stretch (six lysines, K167-K172); predominantly plasma membrane; most commonly mutated in cancer
• •KRAS4A: alternative splice; similar to 4B but shorter polybasic stretch + palmitoylation
• •NRAS: farnesylated + palmitoylated (C181); enriched in Golgi and plasma membrane raft microdomains
• •HRAS: farnesylated + doubly palmitoylated (C181, C184); classically associated with plasma membrane lipid rafts; most potent activator of RAF1

All four isoforms cycle between GTP-bound active and GDP-bound inactive conformations through the same biochemical mechanism, but exhibit distinct nanoscale membrane organization, effector coupling, and oncogenic potency.

The GTPase Cycle: SOS, GAP, and the Nucleotide Switch

Intrinsic GTP hydrolysis: RAS-GTP slowly hydrolyzes its bound GTP to GDP + Pi (t1/2 ~20-30 min intrinsically); this Gln61-mediated catalytic mechanism proceeds via a transition state involving the catalytic glutamine (Q61 in switch II) stabilizing the attacking water molecule. Oncogenic mutations at G12 (G12D, G12V, G12C), G13 (G13D), and Q61 (Q61H, Q61L, Q61R) all impair GTP hydrolysis -- G12/G13 mutations sterically exclude the catalytic arginine finger of GAP proteins; Q61 mutations directly impair the catalytic mechanism.

SOS-mediated GEF activation: Son of Sevenless (SOS1, SOS2) are dual guanine nucleotide exchange factors (GEFs) that catalyze GDP release from RAS, allowing GTP binding (cellular [GTP] >> [GDP]). SOS contains: REM domain (allosteric RAS binding site), Cdc25 domain (catalytic exchange site), DH-PH domain (membrane targeting), proline-rich C-terminal tail (GRB2 SH3 domain binding). Receptor tyrosine kinase activation recruits the GRB2-SOS1 complex to receptor pTyr via GRB2 SH2 domain (or indirectly via SHC), bringing SOS to the plasma membrane near RAS. SOS catalysis: SOS Cdc25 domain binds RAS-GDP at the catalytic site while an allosteric RAS-GTP molecule binds the REM domain back pocket, creating a positive feedback loop -- RAS-GTP allosterically stimulates SOS catalytic activity (~75-fold), generating a bistable switch.

RAS GAPs: GTPase-activating proteins (NF1/Neurofibromin, RASA1/p120GAP, RASAL, IQGAP, DAB2IP) insert an arginine finger into the RAS active site, stabilizing the transition state and accelerating GTP hydrolysis ~100,000-fold. NF1 (Neurofibromin) is the predominant RAS GAP in most tissues; NF1 germline loss-of-function causes neurofibromatosis type 1 (NF1) -- benign neurofibromas and elevated cancer risk due to hyperactive RAS.

Switch I and Switch II Conformations

RAS undergoes dramatic conformational changes between GDP-bound and GTP-bound states, concentrated in two regions:

• •Switch I (residues 30-38): contacts GAP arginine finger; contacts RAF-RBD; Y32 and T35 coordinate Mg2+ and gamma-phosphate in GTP-bound state
• •Switch II (residues 59-76): Q61 catalytic residue; G60-A66 alpha-2 helix rearrangement; effector-binding surface changes dramatically between GDP and GTP states

Both switches adopt the GTP-bound "on" conformation when GTP is loaded, exposing effector binding surfaces for RAF-RAS binding domain (RBD), PI3K p110 RBD, RALGDS, TIAM1, and other effectors.

---

RAS Effectors: RAF, PI3K, and RalGDS

RAS-GTP recruits multiple effector proteins that initiate parallel downstream pathways. The three major effector axes:

1. RAF kinases (RAF1/CRAF, BRAF, ARAF): MAPK cascade -> ERK1/2

2. PI3K p110alpha/gamma: PIP3 -> AKT/mTOR (covered in the mTOR article)

3. RalGDS family (RalGDS, RGL, RGL2): RAL-GEFs -> RALA/RALB GTPases -> exocyst complex, CDC42/RAC, PLD1

The relative engagement of each effector axis is influenced by RAS isoform, membrane localization, and cellular context -- KRAS preferentially activates RAF; HRAS preferentially activates PI3K; differential nanoclustering on lipid domains creates effector selectivity.

---

RAF Kinases: Activation Mechanism and Paradoxical Inhibitor Effects

BRAF, CRAF, ARAF: Domain Architecture

All three RAF kinases share:

• •RBD (RAS-Binding Domain): ubiquitin superfold; binds RAS-GTP Switch I/II; Kd ~20-100 nM for KRAS/HRAS-GTP; critical for membrane recruitment
• •CRD (Cysteine-Rich Domain): binds diacylglycerol and membrane phospholipids; cooperates with RBD for membrane localization; ARAF CRD binds RAS-GTP independently
• •CR2 linker: regulatory region; BRAF: 14-3-3 binding via pS365; CRAF: pS259 14-3-3 binding (inhibitory), pS338 activating
• •Kinase domain (KD): DFG-containing activation loop; hinge region; C-helix (contains conserved E/K salt bridge critical for activation); N-lobe and C-lobe bilobal architecture; phospho-T599/S602 (BRAF) or pT491/pS494 (CRAF) activation loop

BRAF has constitutively high intrinsic kinase activity (due to a glutamic acid E600 mimicking phospho-activation loop) -- BRAF is the primary RAF isoform that directly phosphorylates MEK1/2. BRAF V600E mutation simply creates an even more active kinase by stabilizing the DFG-in active conformation.

CRAF has lower basal kinase activity than BRAF but is the primary effector of RAS in non-V600E contexts; CRAF requires extensive post-translational regulation (SRC-mediated pY340/Y341; pS338 by PAK1; removal of pS259 14-3-3 by PP2A).

RAF Activation by RAS-GTP: The Dimerization Model

RAF activation is fundamentally a dimerization-driven mechanism:

1. RAS-GTP recruits RAF RBD to the plasma membrane

2. Membrane-localized RAF undergoes dimerization (homodimers: BRAF:BRAF, CRAF:CRAF; or heterodimers: BRAF:CRAF)

3. Dimerization relieves CR3 intramolecular inhibition; C-helix rotates inward; DFG flips to "in" (active) conformation

4. Trans-autophosphorylation of activation loop tyrosines (CRAF Y341)

5. Activated RAF kinase domain phosphorylates MEK1-S218/S222 and MEK2-S222/S226

The dimerization interface involves the "RASK" dimerization motif in the C-lobe of the kinase domain -- R506 contacts helix C of the partner RAF; mutation of R509H in BRAF (a naturally occurring variant) abolishes BRAF dimerization.

BRAF V600E: The Most Common BRAF Mutation

BRAF V600E (valine to glutamate at position 600 in the DFG+1 position) is present in ~50% of melanoma, ~60% of papillary thyroid cancer, ~10% of colorectal cancer, and ~5% of non-small cell lung cancer. The V600E mutation:

• •Introduces a negative charge mimicking phospho-T599 (adjacent activation loop residue)
• •Stabilizes the DFG-in active conformation constitutively
• •Renders BRAF catalytically active as a monomer (does not require RAS-GTP or dimerization)
• •Confers ~500-fold higher kinase activity vs wild-type BRAF

V600E BRAF signals constitutively to MEK-ERK without requiring upstream RAS-GTP input -- explaining why BRAF V600E tumors are initially highly sensitive to selective BRAF inhibitors.

Paradoxical ERK Activation by BRAF Inhibitors in RAS-Mutant Cells

First-generation BRAF inhibitors (vemurafenib/PLX4032, PLX4720 for research; dabrafenib for clinical use) are highly selective for BRAF V600E. However, in cells with upstream RAS activation (KRAS/NRAS mutant, or RTK-hyperactivated), these inhibitors paradoxically increase ERK phosphorylation. The mechanism:

1. BRAF inhibitor binds and blocks one protomer of a BRAF:CRAF heterodimer (or BRAF:BRAF homodimer)

2. Inhibitor-bound protomer induces a conformational change that trans-activates the unbound partner protomer (negative allostery -> positive for the partner)

3. In RAS-mutant cells, RAS-GTP drives high RAF dimerization; inhibitor-bound BRAF:CRAF heterodimers have enhanced CRAF catalytic activity

4. Active CRAF phosphorylates MEK-ERK despite BRAF being inhibited

5. Net result: ERK activation is paradoxically increased ("paradoxical ERK activation" or "RAF paradox")

This paradox explains why BRAF inhibitor monotherapy causes cutaneous squamous cell carcinomas (driven by hyperactivated RAS in keratinocytes), and why combination BRAF + MEK inhibition (vemurafenib + cobimetinib; dabrafenib + trametinib) is required to overcome this.

Second-generation "paradox-breaker" BRAF inhibitors (PLX7904, PLX8394) adopt a different binding mode that destabilizes RAF dimerization rather than promoting it, preventing paradoxical activation.

---

MEK1/2 and ERK1/2: The Core Cascade

MEK1/MEK2 (MAP2K1/MAP2K2): Dual-Specificity Kinases

MEK1 and MEK2 are dual-specificity kinases that phosphorylate ERK1/2 on both a tyrosine and a threonine within the activation loop (TEY motif in ERK1/2: T185-E186-Y187 for ERK1; T183-E184-Y185 for ERK2). MEK1/2 are highly substrate-selective -- ERK1/2 are essentially the only substrates of MEK1/2. MEK1/2 share ~80% sequence identity and appear largely functionally redundant though MEK1 may have some MEK2-independent functions.

MEK inhibitors: U0126 (MEK1/2 non-ATP-competitive allosteric inhibitor; binds allosteric pocket adjacent to ATP site; IC50 ~70/60 nM for MEK1/2); PD98059 (MEK1 preferential; non-ATP-competitive; less potent than U0126 in cells; useful historical tool); trametinib (GSK1120212; clinical-grade MEK1/2 allosteric inhibitor; IC50 ~0.7/0.9 nM); cobimetinib, binimetinib, selumetinib -- all clinical-grade MEK inhibitors for research combination studies.

ERK1/2 (MAPK3/MAPK1): The Effector Kinase

ERK1 (44 kDa) and ERK2 (42 kDa) are the effector kinases of the MAPK cascade. Fully activated ERK (doubly phosphorylated, ppERK) has ~1000-fold higher kinase activity than unphosphorylated ERK. ERK1/2 phosphorylate substrates on Ser/Thr-Pro motifs (minimal: PxS/TP; docking-enhanced: FxFP or DEF motif docking, or D-motif/KIM docking).

Nuclear substrates:

• •ELK1 (Ets transcription factor): pT363; drives FOS transcription; immediate early gene response; ERK-ELK1-FOS-JUN cascade within minutes of mitogen stimulation
• •c-FOS: pT325, pT331, pS374; phosphorylation stabilizes c-FOS protein; ERK phospho-FOS is resistant to ubiquitination; c-FOS drives cell cycle entry genes
• •RSK1/2/3/4 (Ribosomal S6 Kinase): ERK phosphorylates RSK on T573 (activation loop T-loop); RSK then autophosphorylates S380 (hydrophobic motif), enabling PDK1 to complete RSK activation; active RSK phosphorylates RPS6, BAD-S75, CREB-S133, TSC2-S1798
• •MSK1/2 (Mitogen and Stress-activated Kinase): ERK + p38 dual-target; MSK phosphorylates CREB-S133 and H3S10; chromatin remodeling at immediate-early gene loci
• •MNK1/2 (MAP Kinase-Interacting Kinase): activated by ERK and p38; phosphorylates eIF4E-S209 (cap-binding protein); promotes cap-dependent translation of structured mRNAs; MNK1/2 inhibitor CGP57380 used to decouple ERK-eIF4E axis
• •MYC: pT58/S62 regulation -- ERK phosphorylates MYC-S62 (stabilizing); GSK3beta subsequently phosphorylates T58 (destabilizing, Fbxw7 degron); ERK and PI3K pathways converge on MYC stability

Cytoplasmic substrates:

• •BIM (BCL2L11): pS69; targets BIM for proteasomal degradation; ERK-mediated BIM suppression promotes cell survival
• •BAD: pS75; promotes BAD/14-3-3 association, preventing BAD-BCL2 interaction
• •PABP (Poly-A Binding Protein): pS92; promotes translation
• •Cytoskeletal proteins: FAK pY397 cooperation; paxillin pS83; caldesmon -- ERK controls cytoskeletal dynamics and migration

---

Scaffolding Proteins: KSR, IQGAP, and MP1

KSR1/2 (Kinase Suppressor of RAS)

KSR1 and KSR2 are pseudokinase scaffold proteins that organize the RAF-MEK-ERK complex. KSR contains: CA1-CA5 conserved domains; CC-SAM (coiled-coil SAM domain; KSR membrane targeting); CRAD (CA3, RAS binding); kinase-like domain (KSR KD). KSR scaffolds MEK in the basal state and is recruited to plasma membrane upon RAS-GTP activation, where it organizes MEK and ERK in proximity to activated RAF. KSR2 also regulates fatty acid oxidation and energy metabolism. KSR is not merely a scaffold but also an allosteric modulator: BRAF:KSR1 heterodimers can activate MEK.

IQGAP1 (IQ Motif-Containing GTPase-Activating Protein 1)

IQGAP1 is a 189 kDa multidomain scaffold that integrates multiple signaling pathways. In the context of ERK signaling, IQGAP1 binds BRAF, MEK1/2, and ERK1/2 simultaneously, organizing a signalosome complex at the plasma membrane and at cortical actin. IQGAP1 also binds CDC42/RAC1 (through its RasGAP-related domain -- though it lacks GAP activity), E-cadherin/beta-catenin, and CLIP-170, integrating cytoskeletal and adhesion signaling with ERK activation.

MP1/LAMTOR3 (MEK Partner 1)

MP1 is a late endosomal scaffold for ERK signaling; it forms a complex with p14/ROBLD3 (LAMTOR2) on late endosomes/lysosomes (Ragulator complex component). MP1 recruits MEK1 and ERK1 to late endosomes, generating an endosome-specific ERK activity compartment distinct from plasma membrane and nuclear ERK pools. This spatial compartmentalization of ERK signaling contributes to signaling specificity -- endosomal ERK may preferentially phosphorylate a distinct substrate subset.

---

Negative Feedback Loops and Signal Termination

ERK exerts extensive negative feedback on its own pathway:

1. ERK -> SOS: ERK phosphorylates SOS1 at multiple C-terminal sites, disrupting the SOS-GRB2 interaction and removing SOS from the receptor complex; reduces RAS-GTP loading

2. ERK -> RAF: ERK phosphorylates CRAF at S289, S296, S301, S642, and BRAF at S151 -- creating negative feedback phosphorylations that reduce RAF-RAS interaction and promote 14-3-3 binding

3. ERK -> EGFR: ERK phosphorylates EGFR T669 in the juxtamembrane domain, reducing EGFR kinase activity (feedback inhibition of upstream RTK)

4. ERK -> MKP/DUSP induction: ERK transcriptionally induces dual-specificity phosphatases (MKP1/DUSP1, MKP3/DUSP6, DUSP4) that dephosphorylate the TEY motif in ERK1/2, rapidly terminating ERK activity; DUSP6 is an ERK-specific cytoplasmic phosphatase that creates a particularly robust negative feedback

5. ERK -> SPRY proteins (Sprouty 1-4): ERK phosphorylates SPRY2-Y55, which enables SPRY2 to sequester GRB2 and prevent SOS membrane recruitment; SPRY proteins are transcriptional targets of ERK

These feedback loops create the transient ERK activation kinetics (peak at 5-15 min, decline by 30-60 min) seen with EGF stimulation, in contrast to the sustained ERK activation (>4 h) seen with NGF/neurotrophin stimulation that drives neuronal differentiation.

---

Research Tools for RAS/MAPK/ERK Investigation

---

Experimental Protocols

Protocol 1: BRAF Inhibitor Paradoxical ERK Activation Assay

Demonstrates the differential response of BRAF V600E vs RAS-mutant cells to BRAF inhibitors -- a critical selectivity control for all BRAF inhibitor research.

Reagents: PLX4720 (BRAF V600E inhibitor, research use; 10 mM stock DMSO), U0126 (MEK inhibitor, positive control), RIPA lysis buffer + PhosSTOP + protease inhibitors, antibodies: pERK1/2-T202/Y204 (CST #4370), total ERK1/2 (CST #4695), pMEK1/2-S217/S221 (CST #9154), total MEK1/2

Cell lines: A375 (BRAF V600E melanoma), SK-MEL-28 (BRAF V600E), A549 (KRAS G12S lung), SW480 (KRAS G12V colon), HCT116 (KRAS G13D colon)

Protocol:

1. Seed cells in 6-well plates; grow to 70% confluence; serum-starve 4 h

2. Treat with PLX4720 (0, 0.1, 0.5, 1, 5, 10 uM) or DMSO; 2 h at 37 degrees C

3. Lyse; Western blot for pERK1/2 and total ERK1/2; pMEK1/2 and total MEK1/2

4. Expected results:

- A375/SK-MEL-28 (BRAF V600E): PLX4720 dose-dependently suppresses pERK (IC50 ~0.1-0.5 uM)

- A549/SW480/HCT116 (KRAS mutant): PLX4720 paradoxically increases pERK at 0.5-5 uM (2-5 fold increase vs vehicle); pMEK may also increase

5. Compare PLX7904 (paradox-breaker): at same concentrations, should suppress BRAF V600E pERK AND reduce/eliminate paradoxical pERK in KRAS-mutant cells

6. Add U0126 (10 uM) as MEK inhibitor positive control -- abolishes pERK in both BRAF V600E and KRAS-mutant cells regardless of paradox

7. Quantify pERK/total ERK band densities; plot as % of vehicle; define paradoxical activation as >150% of vehicle in KRAS-mutant cells

Protocol 2: ERK1/2 Translocation and Nuclear/Cytoplasmic Fractionation

ERK translocates from cytoplasm to nucleus upon activation -- quantifying this translocation is essential for distinguishing cytoplasmic from nuclear ERK functions.

Reagents: Cytoplasmic extraction buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.05% NP-40, 1 mM DTT, protease + phosphatase inhibitors), nuclear extraction buffer (20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM DTT, 10% glycerol, protease + phosphatase inhibitors), EGF (50 ng/ml), serum-free medium, antibodies: pERK1/2, total ERK1/2, GAPDH (cytoplasmic marker), Lamin B1 (nuclear marker)

Protocol:

1. Serum-starve cells 16-18 h (establishes basal, cytoplasmic ERK)

2. Stimulate with EGF (50 ng/ml) for 0, 5, 15, 30, 60 min at 37 degrees C

3. Fractionate: harvest cells in ice-cold PBS; pellet; resuspend in cytoplasmic buffer; 5 min ice; vortex; 750xg 5 min; supernatant = cytoplasmic fraction; pellet = crude nuclear fraction

4. Wash nuclear pellet 3x with cytoplasmic buffer; extract with nuclear buffer (rotate 30 min 4 degrees C); centrifuge 20,000xg 15 min; collect nuclear extract

5. Western blot cytoplasmic and nuclear fractions separately: pERK1/2 + total ERK1/2 + GAPDH (loading/purity) + Lamin B1 (nuclear purity)

6. At 0 min: ERK predominantly cytoplasmic; by 15 min: pERK accumulates in nucleus; by 60 min: ERK returns to cytoplasm (export mediated by MEK, which sequesters inactive ERK); plot nuclear pERK/cytoplasmic pERK ratio vs time

7. MEK inhibitor (U0126 10 uM, 30 min pre): prevents ERK phosphorylation and nuclear translocation; demonstrates phospho-dependent nuclear import

Protocol 3: In-Cell Western (ICW/LI-COR Odyssey) ERK Inhibitor Dose-Response

High-throughput, quantitative pERK measurement in fixed cells -- enables IC50 determination for large inhibitor panels without lysis.

Reagents: 96-well plates (optically clear bottom), 4% PFA fixation, 0.1% Triton X-100, LI-COR Odyssey blocking buffer, anti-pERK1/2-T202/Y204 (CST #4370; IRDye 800CW-conjugated secondary), anti-total ERK1/2 (CST #4695; IRDye 680RD-conjugated secondary), inhibitors at 8-point dose ranges

Protocol:

1. Seed 5000 cells/well in 96-well plates; 24 h adhesion; serum-starve 4 h

2. Add inhibitors (PLX4720, U0126, trametinib, SCH772984) at 8 concentrations (0.001-100 uM, 0.5 log spacing) + DMSO control; 2 h treatment

3. Stimulate with EGF (50 ng/ml) 15 min (or omit if testing BRAF V600E constitutive activation)

4. Fix: aspirate; add 4% PFA 15 min RT; wash 3x PBS; permeabilize 0.1% Triton X-100 10 min; wash; block Odyssey buffer 1 h

5. Primary antibodies (anti-pERK 1:200 + anti-total ERK 1:400) in blocking buffer; overnight 4 degrees C

6. Wash 4x PBST; secondary antibodies (IRDye 800CW anti-rabbit + IRDye 680RD anti-mouse) 1 h RT

7. Scan LI-COR Odyssey (800 nm channel: pERK; 700 nm channel: total ERK); software quantification of fluorescence intensity per well

8. Calculate pERK/total ERK ratio per well; IC50 by 4-parameter logistic regression; Z-prime calculation using max (DMSO + EGF) and min (U0126 + EGF) controls

Protocol 4: RAS-GTP Pulldown (RAF-RBD Affinity Precipitation)

Quantifies active (GTP-bound) RAS in cell lysates using the RAF1-RBD as an affinity reagent.

Reagents: GST-RAF1-RBD (Cys-free, aa 51-131; purified from E. coli; bound to glutathione-Sepharose beads), RAS pulldown lysis buffer (25 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1% NP-40, 1 mM DTT, protease inhibitors), anti-pan-RAS antibody (CST #3965; or isoform-specific anti-KRAS, anti-NRAS), anti-RAS-GTP antibody (New East Biosciences #26908)

Protocol:

1. Prepare EGF stimulation series: serum-starved cells; EGF 50 ng/ml for 0, 2, 5, 10 min; also include KRAS G12V-expressing positive control cells

2. Lyse immediately in ice-cold RAS pulldown buffer (500 ul per well of 6-well plate); centrifuge 16,000xg 15 min 4 degrees C; reserve 50 ul as input

3. Incubate lysate with 30 ul GST-RAF1-RBD beads; rotate 45 min 4 degrees C; wash 3x with lysis buffer; elute with 2x SDS loading buffer

4. Western blot: pulldown eluate + input (total RAS); anti-pan-RAS antibody; compare RAS-GTP (pulldown) vs total RAS (input); calculate ratio

5. EGF stimulation: RAS-GTP peaks at 2-5 min; returns toward baseline by 10-15 min (SOS negative feedback by phospho-SOS); KRAS G12V cells: constitutively high RAS-GTP

6. U0126 pretreatment: ERK inhibition blocks SOS negative feedback; RAS-GTP remains elevated for longer after EGF (confirms ERK->SOS negative feedback)

7. Alternative: use ELISA-based Active RAS Detection Kit (CST #16198) -- quantitative, avoids electrophoresis

Protocol 5: ERK Substrate Phosphorylation Kinetics by Multiplex Luminex or MSD Immunoassay

Simultaneously quantifies multiple ERK substrate phosphorylations (pRSK1-T573, pELK1-S383, pEIF4E-S209, pMYC-S62) in a single sample -- superior to sequential Western blots for pathway breadth assessment.

Reagents: MSD (Meso Scale Discovery) Multi-Spot phospho-protein assay plates, or Luminex-based MILLIPLEX MAP ERK substrate panels, lysis buffer (MSD RIPA or Cell Signaling #9803), EGF stimulation, ERK inhibitor SCH772984 (1 uM), MEK inhibitor trametinib (10 nM)

Protocol:

1. Serum-starve cells; stimulate with EGF (0, 5, 15, 30, 60 min) +/- SCH772984 (ERK inhibitor) or trametinib (MEK inhibitor); harvest in MSD lysis buffer

2. MSD 96-well plate: individual spots functionalized with capture antibodies (anti-pRSK1-T573, anti-pELK1-S383, anti-pEIF4E-S209, anti-pMYC-S62, anti-pERK1/2); add 25-50 ug lysate per well; 1 h shaking RT

3. Wash; add MSD SULFO-TAG detection antibodies (all secondary antibodies in one mix); 1 h; wash; add MSD Read Buffer; read on MSD SECTOR instrument (electrochemiluminescence)

4. Each spot generates quantitative signal proportional to phospho-protein concentration; on-plate calibration curves enable absolute quantification (pg/ml)

5. ERK time course: pERK peaks early (5-15 min); pRSK1 (cytoplasmic substrate, slightly delayed); pELK1 (nuclear substrate, delayed); pEIF4E (via MNK, parallel pathway)

6. SCH772984 vs trametinib: SCH772984 (ERK inhibitor) suppresses all downstream substrates (pRSK1, pELK1, pEIF4E) directly; trametinib (MEK inhibitor) also suppresses all but through MEK->ERK block; confirm that SCH772984 does not suppress pMEK (MEK activity continues but ERK is blocked)

---

Disease Contexts

BRAF V600E Melanoma: Inhibitor Sensitivity and Resistance

A375 and SK-MEL-28 are widely used BRAF V600E melanoma research cell lines that show robust pERK suppression and growth inhibition with PLX4720/vemurafenib (GI50 ~0.1-0.5 uM). Acquired resistance mechanisms include: NRAS amplification or mutation (reactivates CRAF); BRAF V600E amplification; MEK1/2 mutations; COT1/MAP3K8 overexpression; BRAF alternative splicing (p61 truncation bypasses RAS requirement for dimerization). Resistance models generated by long-term inhibitor exposure are used to study combination strategies.

KRAS-Mutant Cancers and G12C Inhibitors

KRAS G12C-specific covalent inhibitors (AMG 510/sotorasib, MRTX849/adagrasib) exploit the unique cysteine at position 12 to form irreversible covalent bonds in the switch-II pocket of GDP-bound KRAS, locking the protein in the inactive state. These agents are used in research contexts at 1-100 nM range. Combination with SHP2 inhibitors (TNO155) or MEK inhibitors overcomes feedback-driven resistance (SHP2 inhibition reduces SOS-mediated RAS-GTP reloading).

ERK Inhibitors for MEK Resistance

In tumors acquiring resistance to MEK inhibitors via MEK1/2 mutations, ERK inhibitors (SCH772984, GDC-0994) can resensitize tumor cells by targeting directly at the ERK level, bypassing MEK mutations. This resistance-overcoming strategy is a major research focus.

---

References

1. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457-2467. PMID: 22589270

2. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11-22. PMID: 12509763

3. Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015;16(5):281-298. PMID: 25907612

4. Pouyssegur J, Volmat V, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol. 2002;64(5-6):755-763. PMID: 12213567

7. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427-430. PMID: 20179705

8. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-977. PMID: 21107323

9. Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10(1):54-71. PMID: 31658955

10. Ramos JW. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol. 2008;40(12):2707-2719. PMID: 18562239

11. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 2005;6(11):827-837. PMID: 16227978

13. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. PMID: 12068308

---

All compounds and reagents described are for Research Use Only (RUO). Not intended for diagnostic, therapeutic, or any human or animal use. Researchers should follow all applicable institutional and regulatory guidelines when handling these materials.